These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12847332)

  • 1. Pentostatin for the treatment of chronic graft-versus-host disease in children.
    Goldberg JD; Jacobsohn DA; Margolis J; Chen AR; Anders V; Phelps M; Vogelsang GB
    J Pediatr Hematol Oncol; 2003 Jul; 25(7):584-8. PubMed ID: 12847332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease.
    Jacobsohn DA; Chen AR; Zahurak M; Piantadosi S; Anders V; Bolaños-Meade J; Higman M; Margolis J; Kaup M; Vogelsang GB
    J Clin Oncol; 2007 Sep; 25(27):4255-61. PubMed ID: 17878478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
    Margolis J; Vogelsang G
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentostatin in steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
    J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.
    Milgrom SA; Nieto Y; Pinnix CC; Smith GL; Wogan CF; Rondon G; Medeiros LJ; Kebriaei P; Dabaja BS
    J Med Case Rep; 2016 Jul; 10():209. PubMed ID: 27465468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
    Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
    Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease.
    Higman M; Vogelsang GB; Chen A
    Expert Opin Pharmacother; 2004 Dec; 5(12):2605-13. PubMed ID: 15571477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study.
    Jacobsohn DA; Gilman AL; Rademaker A; Browning B; Grimley M; Lehmann L; Nemecek ER; Thormann K; Schultz KR; Vogelsang GB
    Blood; 2009 Nov; 114(20):4354-60. PubMed ID: 19745067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypical and functional characterization of bone marrow mesenchymal stem cells in patients with chronic graft-versus-host disease.
    Wang B; Hu Y; Liu L; Hu K; Tie R; He Y; Fu S; Zhu N; Luo Y; Yu X; Huang H
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1020-8. PubMed ID: 25708216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.
    Mohty M; Bilger K; Jourdan E; Kuentz M; Michallet M; Bourhis JH; Milpied N; Sutton L; Jouet JP; Attal M; Bordigoni P; Cahn JY; Sadoun A; Ifrah N; Guyotat D; Faucher C; Fegueux N; Reiffers J; Maraninchi D; Blaise D
    Leukemia; 2003 May; 17(5):869-75. PubMed ID: 12750699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
    Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
    Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative transplants: preclinical and clinical results.
    Sandmaier BM; McSweeney P; Yu C; Storb R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia.
    Teuffel O; Schrauder A; Sykora KW; Zimmermann M; Reiter A; Welte K; Schrappe M
    Bone Marrow Transplant; 2005 Jul; 36(2):145-50. PubMed ID: 15908976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin.
    Klein SA; Bug G; Mousset S; Hofmann WK; Hoelzer D; Martin H
    Br J Haematol; 2011 Jul; 154(1):143-6. PubMed ID: 21477160
    [No Abstract]   [Full Text] [Related]  

  • 15. CD34+ stem cell augmentation of allogeneic, elutriated marrow grafts improves engraftment but cyclosporine A is still required to reduce GVHD and morbidity.
    Noga SJ; Vogelsang GB; Seber A; Davis JM; Schepers K; Hess AD; Jones RJ
    Transplant Proc; 1997; 29(1-2):728-32. PubMed ID: 9123500
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of aGVHD and cGVHD according to relapse status on survival rate in patients with acute lymphocytic leukemia.
    Sayehmiri K; Carson KV; Bakhtiyari S; Shokouhi S; Alimoghadam K
    Hematology; 2014 Dec; 19(8):441-7. PubMed ID: 24620946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.